Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease—A Meta-Analysis

Effect of resveratrol on non‑alcoholic fatty liver disease

(2019) Marios Theodotou et al.   Experimental and Therapeutic Medicine

Non-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment

(2019) Emilio Molina-Molina et al.   Clinics and Research in Hepatology and Gastroenterology

Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression

(2019) Xing-Xing Chen et al.   Frontiers in Endocrinology

Diet-Induced Rat Model of Gradual Development of Non-Alcoholic Fatty Liver Disease (NAFLD) with Lipopolysaccharides (LPS) Secretion

(2019) Dominika Maciejewska et al.   Diagnostics

No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease

(2018) Marianne K. Poulsen et al.   DIABETES OBESITY & METABOLISM

Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

(2018) Somayyeh Asghari et al.   JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION

Non-alcoholic fatty liver disease (NAFLD) – epidemic of the XXI century

(2018) Dominika Maciejewska et al.   Postepy Higieny I Medycyny Doswiadczalnej

Systematic Review and Meta-Analysis Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis

(2017)   Journal of Gastrointestinal and Liver Diseases

Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials

(2017) Tomasz Charytoniuk et al.   NUTRITION

Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population

(2016) Lin-Yan Qian et al.   MEDICINE

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

(2016) Sara Heebøll et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials

(2016) Chongyang Zhang et al.   PLoS One

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

(2015) Forouzan Faghihzadeh et al.   BRITISH JOURNAL OF NUTRITION

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial

(2015) Shihui Chen et al.   DIGESTIVE AND LIVER DISEASE

Properties of Resveratrol:In VitroandIn VivoStudies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans

(2015) J. Gambini et al.   Oxidative Medicine and Cellular Longevity

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

(2014) Veronique S. Chachay et al.   Clinical Gastroenterology and Hepatology

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

(2014) Forouzan Faghihzadeh et al.   NUTRITION RESEARCH

Effects of resveratrol and other polyphenols in hepatic steatosis

(2014) Leixuri Aguirre   WORLD JOURNAL OF GASTROENTEROLOGY

Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial

(2013) S. Bo et al.   CURRENT MEDICINAL CHEMISTRY

Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD

(2013) Amedeo Lonardo et al.   CURRENT PHARMACEUTICAL DESIGN

The global NAFLD epidemic

(2013) Rohit Loomba et al.   Nature Reviews Gastroenterology & Hepatology

High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

(2012) M. M. Poulsen et al.   DIABETES

Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis

(2012) Federico Salamone et al.   Translational Research

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

(2011) Silvie Timmers et al.   Cell Metabolism

Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis

(2011) Federico Salamone et al.   DIGESTIVE AND LIVER DISEASE

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE